IGF1 and cancer: The strategies to target IGF-1 system in cancer consist of [1] reducing circulating ligand levels or bioactivity [2,22] blocking receptor function using receptor-specific antibodies or small-molecule tyrosine kinase inhibitors [1,23,24] and [3] activating AMP-activated protein kinase (AMPK) [25].